At the Albany Medical Center, we have a long-term experience, mean follow-up of 75 months, in 50 renal transplant recipients treated with maintenance sirolimus, prednisone and a calcineurin-inhibitor sparing immunosuppressive regimen. One-year patient and graft survival was 98% and six-year patient and graft survival was 82% and 72% respectively. The rate of early acute rejection (<3 months) was only 10%. Furthermore, no late (>3 months) acute rejection episodes developed despite calcineurin-inhibitor dose minimization. In addition, recipient mean serum creatinine remained stable at 1.6 mg/dl throughout the 6-year follow-up period. Sirolimus is an effective maintenance immunosuppressive agent that safely allows for a reduction in calcineurin-inhibitor dosing.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.trim.2008.08.011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Long Term Outcomes of Transplant Recipients Comparing Belatacept vs. Tacrolimus: A UNOS Database Analysis.
Clin Transplant
February 2025
Department of Transplant Nephrology, Transplant Surgery Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Calcineurin inhibitors have been the choice for maintenance immunosuppression (IS) in kidney transplant recipients (KTR), but they are associated with nephrotoxicity and metabolic side effects. We aim to compare the long-term outcomes of KTR on belatacept (bela) versus tacrolimus (tac) IS, in all KTRs and various subgroups. Using the UNOS-STAR files, we identified adult first-KTR from 2010 to 2022.
View Article and Find Full Text PDFSuccessful Switch to Obinutuzumab in a Rituximab-Intolerant Child with Difficult-to-Treat Idiopathic Nephrotic Syndrome.
J Clin Med
January 2025
Department of Paediatrics, Nephrology and Hypertension, Medical University of Gdansk, 80-210 Gdansk, Poland.
: Idiopathic nephrotic syndrome (INS) is the most common cause of nephrotic syndrome in children. A hallmark of the disease is the rapid remission of proteinuria following a high dose of steroids. Recurrent disease or steroid dependence are common, leading to a high steroid burden and the introduction of steroid sparing therapy.
View Article and Find Full Text PDFRationale for the Use of Topical Calcineurin Inhibitors in the Management of Oral Lichen Planus and Mucosal Inflammatory Diseases.
Cureus
November 2024
Biotechnology, Lipella Pharmaceuticals, Pittsburgh, USA.
Article Synopsis
- - Oral lichen planus (OLP) is a chronic inflammatory autoimmune condition affecting the mouth, often leading to decreased quality of life and potential cancer risks; traditional treatment primarily involves topical corticosteroids, which have undesirable side effects.
- - Interest is growing in alternative treatments, particularly topical calcineurin inhibitors (TCIs) like tacrolimus, which provide a steroid-sparing option and aim for localized effectiveness with less systemic absorption.
- - The management of OLP is complex and requires various treatment strategies; ongoing research is focused on developing safer, more effective therapies, including innovative drug delivery systems and biologics, to improve patient outcomes.
Safety and Efficacy of Everolimus Use to Preserve Renal Function in Intestinal and Multivisceral Transplantation Patients.
Transplant Proc
December 2024
Henry Ford Hospital, Detroit, Michigan.
Background: As calcineurin inhibitors are associated with renal impairment post intestinal transplant, use of everolimus (EVR) may provide renal-sparing benefits.
Methods: We performed a retrospective analysis focused on EVR use and renal function after intestinal or multivisceral transplant. No prisoners were used in the study.
Prolonged remission after cyclophosphamide or tacrolimus treatment in childhood nephrotic syndrome: a cohort study.
Pediatr Nephrol
November 2024
Division of Nephrology, The Hospital for Sick Children, Toronto, ON, Canada.
Background: Steroid-sparing immunosuppression is used in 50% of children with nephrotic syndrome, to prevent relapses and steroid-related toxicity. However, rates and predictors of prolonged remission after cyclophosphamide and tacrolimus are uncertain.
Methods: Retrospective analysis of children (1-18 years) enrolled in a longitudinal cohort.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!